

# Agenus focuses on its lead PD-1 and CTLA-4 programs, its AGEN1181 breakthrough potential antibody and therapeutic strategies for COVID-19 by leveraging its capabilities

\$50M in expected cost savings by streamlining its operations

COVID-19 has changed our lives in unsettling ways. Agenus has been at the front of this pandemic with aggressive actions to protect our employees, our communities, and our business. Our operations in Berkeley, Lexington, and Cambridge are continuing, with minimal interruption.

Most recently, we executed a proactive plan to achieve our critical initiatives, such as advancing our lead programs for potential BLA filings, advancing our next-gen CTLA-4 (AGEN1181) which has shown impressive clinical activity, and initiation of several COVID-19 therapeutic strategies. In addition we scaled back certain R&D programs and streamlined our operations. These initiatives are expected to reduce our burn rate by nearly \$50M over the next 12 months.

## Our lead programs on track for potential BLA filings

**We have completed accrual in our trials of balstilimab (anti-PD-1) monotherapy and in combination with zalifrelimab (anti-CTLA-4) in second line cervical cancer. Last month, we reported an improved response rate of [26.5%](#) (4 CRs, 5 PRs, 8SDs) compared to our initial interim analysis data (ORR of 20.6%). This suggests that the benefit we are seeing with our combination agents**

**in cervical cancer patients is improving over time. This combination may represent a best-in-class, off-the-shelf treatment option in a broad population of patients.**

With COVID-19 concerns, which have affected all aspects of our lives and the lives of our patients, our teams are managing the safety of patients enrolled in our trials to ensure that all treatments and follow-ups are completed in the safest possible way. We are providing *secured* transportation for patients to enable them to visit sites safely and on schedule. In addition to meeting target

accrual, we have continued to collect the necessary data on all of our patients while instituting important measures, such as remote monitoring, to ensure the safety of all involved in the process.

*We commend the tremendous work of our healthcare workers, our patients, and their families during this most challenging time. They have shown their unyielding commitment to advance breakthrough therapies for many patients to come. We are grateful for their tireless work.*

## Next gen CTLA-4 (AGEN1181) trial is deemed as “potentially life-saving treatment” and continues to enroll patients at an impressive pace

AGEN1181 has yielded early exciting results at low doses as both monotherapy and in combination with balstilimab for patients with late stage cancers. Our principal investigators have informed Agenus that based on the potential life-saving attributes of AGEN1181, they expect to continue to accrue amidst the COVID-19 crisis, which has converted many of America’s major hospitals into “COVID exclusive” medical centers. Our study is recruiting patients at multiple major academic cancer centers with deep clinical trial and crisis management experience.

*AGEN1181 was designed to 1) Improve efficacy vs. 1st gen CTLA-4 agents and 2) Broaden the population of responders. We are seeing early clinical signals.*

**As previously reported, we have seen responses with AGEN1181 as monotherapy or in combination with balstilimab. Importantly, other cases of objective responses seem to be emerging less than 3 months after we initiated the combination study.** Earlier, we reported a complete responder to AGEN1181 monotherapy in MSS-endometrial cancer. Based on this and a number of other immune prognostic factors, this patient was unlikely to respond to IO therapies. She was PD-L1 negative, had a

genetic polymorphism that renders patients unlikely to respond to 1st generation anti CTLA-4s such as Yervoy, in addition to her microsatellite stable (MSS) status. So far, the majority of evaluable patients in our trial have experienced disease stabilization after having progressed on prior treatments.

## Agenus has initiated several programs designed to provide therapeutic BENEFIT for COVID-19 patients and to protect health care workers

We recently initiated a program to **protect healthcare workers**, through protective mucosal immunity with our saponin based adjuvant rinse. We are also pursuing a therapeutic approach **for infected patients at high risk for developing severe illness.** This and our other potential therapeutic strategies could have the added benefit of going beyond COVID-19 and provide therapeutic benefit to other SARS-CoV viruses as well as mutated strains of the current virus.

1. **Our saponins and QS-21 may provide prophylactic and therapeutic benefit against COVID-19.** QS-21 is a critical contributor of efficacy in GSK’s shingles vaccine, which has an unprecedented >90% efficacy. QS-21 is known to potentiate immune responses to viral, bacterial and parasitic antigens and increase the titer of disease fighting antibodies.

2. **Our novel allogeneic cell therapy has potential to induce a rapid antiviral innate response by replenishing an important subgroup of immune cells** which constitute a first line of defense against viruses and other pathogens. In addition, they enhance adaptive antibody (B cell) and cellular (T cell) immunity. **Compared to other cell therapy approaches against COVID-19, our cell therapy offers several advantages:** they are monoclonal; their activation can be enhanced by administering a lipid derivative which we have in our portfolio; and they have in-built mechanisms for depletion when their work is completed.
3. **A combination of our clinical stage checkpoint antibodies with QS-21 could help COVID-19 symptomatic patients by reinvigorating exhausted T cells and expanding effector immune cell population.**

**We have rapid discovery capabilities to combat COVID-19 and other pandemic threats – which constitute a logical extension of our capabilities to leverage the immune system to combat cancer and beyond. It was only a matter of time for us to explore these applications. The COVID-19 crisis has accelerated this process based on both our high sense of responsibility and our innate capabilities.**